Novabay Pharmaceuticals, INC DEF 14A proxy statements

NovaBay Pharmaceuticals' CEO David Lazar resigned, effective upon the transfer of his preferred stock and rights to R01 Fund LP and Framework Ventures IV L.P., who are expected to collectively own 90% of the company's common stock.

NovaBay Pharmaceuticals announces a strategic pivot with a new $6.0 million investment from David E. Lazar, leading to significant shareholder dilution and a planned reverse stock split.

NovaBay Pharmaceuticals provided important details regarding its $0.80 per share special cash dividend and announced the record and meeting dates for its 2025 Annual Meeting of Stockholders.

NovaBay Pharmaceuticals is seeking stockholder approval to dissolve the company and liquidate its assets following the sale of its Avenova and wound care assets.

NovaBay Pharmaceuticals engages Lucid Capital Markets to explore strategic alternatives, including a potential business combination, as it faces uncertainty regarding stockholder approval for the company's proposed liquidation and dissolution.

NovaBay Pharmaceuticals' stockholders did not approve the proposed liquidation and dissolution plan at a special meeting, prompting the company to schedule another vote.

NovaBay Pharmaceuticals has finalized the sale of its Avenova eyecare business for $11.5 million and further adjourned its special meeting to allow more time for stockholders to vote on the company's dissolution.

NovaBay Pharmaceuticals is urging stockholders to vote in favor of the proposed sale of Avenova and the subsequent liquidation and dissolution of the company at the reconvened special meeting on December 18, 2024.

NovaBay Pharmaceuticals is urging stockholders to vote in favor of the proposed sale of its eyecare business and subsequent dissolution at a reconvened special meeting on December 18th.

NovaBay Pharmaceuticals has adjourned its special meeting to December 18, 2024, to allow more time for stockholders to vote on the proposed sale of Avenova and the company's liquidation.

Institutional Shareholder Services (ISS) recommends NovaBay stockholders vote in favor of the proposed sale of its Avenova business and the subsequent liquidation of the company.

NovaBay Pharmaceuticals is urging shareholders to vote their shares ahead of the upcoming special meeting on November 22, 2024.

NovaBay Pharmaceuticals has agreed to sell its Avenova eyecare business to PRN Physician Recommended Nutriceuticals for $11.5 million, up from a previous $9.5 million, and plans to liquidate the company.

NovaBay Pharmaceuticals reminds shareholders to vote their shares before the upcoming Special Meeting of Stockholders scheduled for November 22, 2024.

NovaBay Pharmaceuticals has accepted a revised offer from PRN Physician Recommended Nutriceuticals, increasing the purchase price for NovaBay's eyecare business to $11.5 million.

NovaBay Pharmaceuticals has determined that an unsolicited offer from Refresh Acquisitions BidCo LLC to acquire its Avenova brand and related assets is a superior proposal to its existing asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC.

NovaBay Pharmaceuticals is seeking stockholder approval to sell its Avenova business and dissolve the company, aiming to distribute remaining assets to stockholders.

NovaBay Pharmaceuticals has entered into a definitive agreement to sell its Avenova brand and business assets to PRN Physician Recommended Nutriceuticals for $9.5 million in cash, pending stockholder approval and customary closing conditions.

Novabay Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

NovaBay Pharmaceuticals is asking stockholders to vote on several proposals at its upcoming annual meeting, including the election of directors, ratification of the accounting firm, approval of share issuances related to warrant exercises and convertible notes, and a reverse stock split.